{"id":478330,"date":"2021-04-19T16:33:18","date_gmt":"2021-04-19T20:33:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\/"},"modified":"2021-04-19T16:33:18","modified_gmt":"2021-04-19T20:33:18","slug":"meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\/","title":{"rendered":"MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">LONDON and NEW YORK, April  19, 2021  (GLOBE NEWSWIRE) &#8212; MeiraGTx Holdings\u00a0plc\u00a0(Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that\u00a0Alexandria Forbes, Ph.D., president and chief executive officer, and Stuart Naylor, Ph.D., chief development officer, will participate in a fireside chat at the Chardan Virtual Genetic Medicines Manufacturing Summit on Monday, April 26, 2021 at 1:45 p.m. ET.<\/p>\n<p>A live webcast of the presentation will be available on the Investors page of the Company\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=89g0mn6mOR0EzrmpRyTjTHUjwK0X98R6V5Lz7zLb7GrmDsEOwUjgefGzaw6N5mYd2k0WG8TN9A4AqnFhxC6P6bJ4P7tjCP_lHUWn-abUEL6W6QZl7nP3ormnCu_xVQmK\" rel=\"nofollow noopener\" target=\"_blank\">www.investors.meiragtx.com<\/a>. A replay of the webcast will be available for approximately 90 days following the presentation.<\/p>\n<p>\n        <strong>About\u00a0MeiraGTx<\/strong><br \/>\n        <br \/>MeiraGTx\u00a0(Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs.\u00a0MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team,\u00a0MeiraGTx\u00a0has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx\u2019s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.<\/p>\n<p>For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LoWoTpVOFt771JbhWMtEi-lwtoCoGmKH5aFDUrJeHRdj103Iwy3joibDNU365vcLEATzpe2G2k7XT_SA7255WQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.meiragtx.com<\/a>.<\/p>\n<p>\n        <strong>Contacts <\/strong>\n      <\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>MeiraGTx<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5z1TDZlpoaKX22hKWp8v-a4xnuh9fwhNb_f9lPN6cJGdVirqO_mQH8Jw-SENat3C3jJ1frqLf84jjWHBjS66Pu0DPvK1jhBkTEf-G-ld0NE=\" rel=\"nofollow noopener\" target=\"_blank\">Investors@meiragtx.com<\/a><\/p>\n<p>\n        <strong>or<\/strong>\n      <\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>W2O pure<br \/>Ben Rickles <br \/>(404) 502-6766 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HqIP-t81R4oX2VAqcn1TRtxhVb0ZpGmlAHO3rT-lc9WlZsuek6sMEPQqZkqm3WmltSkC8fws6EOcyuyr0oTpaWxgTeK1tJzZjE7ZPwg7Ox2O8o-xYk-EEZsL5AGI21kj\" rel=\"nofollow noopener\" target=\"_blank\">brickles@purecommunications.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxOTU2NCM0MTI3ODQ4IzIxMDA0MTQ=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/902913b7-9f2c-47ee-a42f-040e40d02592\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LONDON and NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) &#8212; MeiraGTx Holdings\u00a0plc\u00a0(Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that\u00a0Alexandria Forbes, Ph.D., president and chief executive officer, and Stuart Naylor, Ph.D., chief development officer, will participate in a fireside chat at the Chardan Virtual Genetic Medicines Manufacturing Summit on Monday, April 26, 2021 at 1:45 p.m. ET. A live webcast of the presentation will be available on the Investors page of the Company\u2019s website at\u00a0www.investors.meiragtx.com. A replay of the webcast will be available for approximately 90 days following the presentation. About\u00a0MeiraGTx MeiraGTx\u00a0(Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-478330","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LONDON and NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) &#8212; MeiraGTx Holdings\u00a0plc\u00a0(Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that\u00a0Alexandria Forbes, Ph.D., president and chief executive officer, and Stuart Naylor, Ph.D., chief development officer, will participate in a fireside chat at the Chardan Virtual Genetic Medicines Manufacturing Summit on Monday, April 26, 2021 at 1:45 p.m. ET. A live webcast of the presentation will be available on the Investors page of the Company\u2019s website at\u00a0www.investors.meiragtx.com. A replay of the webcast will be available for approximately 90 days following the presentation. About\u00a0MeiraGTx MeiraGTx\u00a0(Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research &hellip; Continue reading &quot;MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-19T20:33:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxOTU2NCM0MTI3ODQ4IzIxMDA0MTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit\",\"datePublished\":\"2021-04-19T20:33:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\\\/\"},\"wordCount\":272,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxOTU2NCM0MTI3ODQ4IzIxMDA0MTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\\\/\",\"name\":\"MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxOTU2NCM0MTI3ODQ4IzIxMDA0MTQ=\",\"datePublished\":\"2021-04-19T20:33:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxOTU2NCM0MTI3ODQ4IzIxMDA0MTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxOTU2NCM0MTI3ODQ4IzIxMDA0MTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\/","og_locale":"en_US","og_type":"article","og_title":"MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit - Market Newsdesk","og_description":"LONDON and NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) &#8212; MeiraGTx Holdings\u00a0plc\u00a0(Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that\u00a0Alexandria Forbes, Ph.D., president and chief executive officer, and Stuart Naylor, Ph.D., chief development officer, will participate in a fireside chat at the Chardan Virtual Genetic Medicines Manufacturing Summit on Monday, April 26, 2021 at 1:45 p.m. ET. A live webcast of the presentation will be available on the Investors page of the Company\u2019s website at\u00a0www.investors.meiragtx.com. A replay of the webcast will be available for approximately 90 days following the presentation. About\u00a0MeiraGTx MeiraGTx\u00a0(Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research &hellip; Continue reading \"MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-19T20:33:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxOTU2NCM0MTI3ODQ4IzIxMDA0MTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit","datePublished":"2021-04-19T20:33:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\/"},"wordCount":272,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxOTU2NCM0MTI3ODQ4IzIxMDA0MTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\/","name":"MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxOTU2NCM0MTI3ODQ4IzIxMDA0MTQ=","datePublished":"2021-04-19T20:33:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxOTU2NCM0MTI3ODQ4IzIxMDA0MTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxOTU2NCM0MTI3ODQ4IzIxMDA0MTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/meiragtx-to-present-at-chardan-5th-annual-genetic-medicines-manufacturing-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/478330","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=478330"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/478330\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=478330"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=478330"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=478330"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}